Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

FDA Approves Extended-Release Amantadine (GOCOVRI™) for Treatment of Dyskinesia

Statement from the Parkinson's Foundation Medical Director, Michael Okun, MD

"Today, Adamas announces FDA approval of an extended release amantadine capsule called GOCOVRI. This drug will provide a practical once a day solution for dyskinesia management and reducing "off" time. Patients who are currently well managed using multiple doses per day of generic amantadine for dyskinesia will not likely derive additional symptomatic benefits from switching to once a day dosing; however, patients experiencing side effects from amantadine may wish to discuss options with their neurologist.

Both GOCOVRI and generic amantadine use is linked to a risk of side effects such as dizziness, hallucinations or blotching on the skin of the legs.  If you are considering starting this medicine or switching to this medicine we recommend consulting with your doctor.

In an independent Parkinson's Foundation study prior to this approval, we found that generic amantadine use improved dyskinesia in patients.  However, amantadine use does have a risk of side effects including insomnia and hallucinations. GOCORVI has been designed to limit the risk of these complications and it will not carry generic amantadine's warning for insomnia."

Call our Helpline, 1-800-4PD-INFO, or visit www.GOCOVRI.com for more information.

About the Parkinson's Foundation

The Parkinson's Foundation is working toward a world without Parkinson's disease. Formed by the merger of National Parkinson Foundation (NPF) and the Parkinson's Disease Foundation (PDF), the mission of the Parkinson's Foundation is to invest in promising scientific research that will end Parkinson's disease and improve the lives of people with Parkinson's, and their families, through improved treatments, support and the best care. For more information, visit www.parkinson.org, or call (800) 4PD-INFO (473-4636).

About Parkinson's Disease (PD)

Affecting an estimated one million Americans and 10 million worldwide, PD is the second-most common neurodegenerative disease after Alzheimer's and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for PD and 60,000 new cases are diagnosed each year in the United States alone.

# # #

Friday, August 25, 2017
Parkinson’s Foundation Announces New Podcast With Research, Findings And Advice For Patients, Healthcare Professionals, And General Community
Tuesday, August 1, 2017

'Substantial Matters: Life and Science of Parkinson's' Podcast Now Available Online

Parkinson’s Foundation Appoints Sean Kramer as Chief Development Officer
Tuesday, July 11, 2017

NEW YORK & MIAMI — The Parkinson’s Foundation today announced its hiring of Sean Kramer as Senior Vice President, Chief Development Officer. The noted non-profit leader will oversee fundraising initiatives for the national organization, working from its offices in New York and Miami.

The Parkinson’s Foundation’s Fall Moving Day® Walks Fund Local Parkinson’s Programs
Thursday, June 8, 2017

Seven Cities Receive Community Grants 

Parkinson’s Foundation Mourns the Loss of Tom Isaacs
Thursday, June 8, 2017

The Parkinson’s Foundation mourns the loss of Tom Isaacs, a dear friend and renowned global advocate for the Parkinson’s community. Tom passed away on May 31 at the age of 49.

Tom was diagnosed with young onset Parkinson’s more than 20 years ago. He quickly became active in the fight against Parkinson’s in his native UK and as part of the global community.

Parkinson’s Foundation to Host “World Without Parkinson’s” Symposium on Thursday, June 1 to Mark 60th Anniversary
Wednesday, May 31, 2017

Scientific Progress in Next 20 Years Due to Outpace the Last 200

Parkinson’s Foundation Welcomes New Patient Advisors
Wednesday, May 24, 2017

Five New Members Added to Advisory Council to Improve Lives of People Living With Parkinson’s

New York, NY, and Miami, FL — The Parkinson’s Foundation is pleased to welcome five new members to its People with Parkinson’s Advisory Council.  The appointments reflect the foundation’s ongoing commitment to engage with the community in its work to create a world without Parkinson’s disease.

Fifth Annual Celebrate Spring Boston Raises More Than $30,000 for Parkinson’s Foundation
Thursday, May 11, 2017

Boston Area Residents Inspire Fellow Young Professionals to End Parkinson’s

Parkinson’s Foundation Welcomes Paul H. Nathan to Board of Directors
Wednesday, May 3, 2017

New York, NY and Miami, FL — The Parkinson’s Foundation is pleased to announce the election of financial services executive Paul H. Nathan of San Francisco, CA, to its Board of Directors. The appointment was announced following a meeting of the board on April 27.

Parkinson’s Foundation to Host “World Without Parkinson’s” Scientific Symposium on June 1 in NYC
Friday, April 21, 2017

The Parkinson’s Foundation invites health innovators to join World Without Parkinson’s on Thursday, June 1 in New York, NY. The cutting-edge scientific event marks the 200th anniversary of James Parkinson’s, “An Essay on the Shaking Palsy.”

FDA Allows Marketing of a Genetic Test for Medical Conditions Including Parkinson’s
Thursday, April 6, 2017

Earlier today, the US Food and Drug Administration (FDA) announced that it will allow direct marketing to consumers of a genetic test that identifies predispositions for 10 medical conditions, including Parkinson’s. Such tests are referred to as direct-to-consumer or DTC.

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.